CJC-1295 No DAC
+ Ipamorelin
CJC-1295 No DAC and Ipamorelin are two structurally distinct, mechanistically
complementary growth hormone secretagogue peptides widely used in preclinical and
cell-based research models investigating somatotropic axis regulation and pulsatile
growth hormone release dynamics. Baltic Peptides supplies both compounds as individually
lyophilised research peptides at ≥99% analytical purity, independently verified by
third-party HPLC and mass spectrometry analysis.
This combination is made available exclusively for in vitro and preclinical
research purposes by qualified scientific investigators and licensed research institutions.
Both Compounds Third-Party Verified · COA Per Compound · EU Dispatch
GHRH Analogue
≥99%
GH Secretagogue
≥99%
Key Features
-
Purity (both compounds) — ≥99% by HPLC analysis
-
Form — Lyophilised powder, individual single-use vials
-
Storage (long-term) — −20 °C, protected from light
-
Storage (short-term) — 2–8 °C, up to 4 weeks
-
Solubility — Sterile water or bacteriostatic water
-
Classification — Research Use Only (RUO)
-
Testing — Independent third-party batch verification
-
Documentation — Separate COA issued per compound per batch
Scientific Overview
Compound Background
CJC-1295 No DAC and Ipamorelin represent two pharmacologically distinct approaches to
stimulating growth hormone (GH) secretion from the anterior pituitary in preclinical
research models. While each compound acts through separate receptor classes, they are
frequently used in combination in research settings due to their mechanistically
complementary modes of action — engaging both the GHRH receptor pathway and the
ghrelin/GHS-R1a receptor pathway simultaneously to investigate additive or synergistic
effects on GH release dynamics.
CJC-1295 No DAC (also referred to as Mod GRF 1-29) is a 29-amino acid synthetic
analogue of endogenous growth hormone-releasing hormone (GHRH). The “No DAC” designation
specifies the absence of a Drug Affinity Complex modification, resulting in a shorter
plasma half-life (approximately 30 minutes in animal models) and a more physiologically
pulsatile GH release pattern compared to DAC-containing variants. This kinetic profile
is frequently preferred in research protocols examining pulsatile GH secretion dynamics.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) and selective
ghrelin receptor (GHS-R1a) agonist developed for its high GH secretagogue potency and
notable receptor selectivity. Unlike earlier GHRP-class compounds such as GHRP-2 and
GHRP-6, Ipamorelin exhibits minimal off-target stimulation of ACTH, cortisol, or
prolactin at research-relevant concentrations, making it a preferred tool compound
in studies requiring isolated examination of the GH axis.
Mechanisms of Action (Research Context)
The two peptides engage distinct but physiologically linked receptor systems involved in
the central and pituitary regulation of somatotropic function:
-
CJC-1295 No DAC — GHRH receptor (GHRH-R) agonism: Acting as a functional
GHRH analogue, CJC-1295 No DAC binds and activates the pituitary GHRH receptor, stimulating
adenylyl cyclase, increasing intracellular cAMP, and promoting GH synthesis and secretion from
somatotroph cells. The compound preserves endogenous pulsatility because its shorter half-life
allows receptor resensitisation between dosing intervals — a feature of interest in research
models examining physiological GH secretion patterns. -
Ipamorelin — GHS-R1a (ghrelin receptor) agonism: Ipamorelin activates the
growth hormone secretagogue receptor type 1a via a ghrelin-mimetic mechanism, stimulating GH
release through a pathway independent of — and additive to — the GHRH-R pathway. At the
pituitary level, GHS-R1a activation also amplifies the GH response to GHRH-receptor
stimulation, which forms the mechanistic rationale for combined use of these two compound
classes in preclinical research models. -
Dual-pathway research utility: The simultaneous engagement of GHRH-R and
GHS-R1a by CJC-1295 No DAC and Ipamorelin respectively enables researchers to examine
synergistic somatotropic axis modulation, making this combination a frequently referenced
tool in preclinical studies of GH pulsatility, IGF-1 regulation, and hypothalamic-pituitary
signalling architecture.
Research note on combined use: The co-administration of GHRH analogues and
GHS-R1a agonists in preclinical models has been documented to produce additive effects on GH
pulse amplitude compared to either compound alone. This is attributed to the convergent but
mechanistically distinct signalling inputs to pituitary somatotrophs from both receptor classes.
animal model data. No clinical claims are implied or intended. Both compounds are supplied
exclusively for laboratory investigation by qualified researchers.
Technical Specifications
| Parameter | CJC-1295 No DAC | Ipamorelin |
|---|---|---|
| Common Name | CJC-1295 No DAC (Mod GRF 1-29) | Ipamorelin |
| Compound Class | GHRH Analogue (29-mer) | GHS-R1a Agonist (Pentapeptide) |
| Molecular Formula | C₁₅₂H₂₅₂N₄₂O₄₂ |
C₃₈H₄₉N₉O₅ |
| Molecular Weight | 3367.97 g/mol | 711.87 g/mol |
| CAS Number | 863288-34-0 |
170851-70-4 |
| Purity | ≥99% (HPLC verified) | ≥99% (HPLC verified) |
| Form | Lyophilised powder | Lyophilised powder |
| Appearance | White to off-white powder | White to off-white powder |
| Solubility | Sterile water, bacteriostatic water | Sterile water, bacteriostatic water, dilute acetic acid |
| Long-Term Storage | −20 °C, desiccated, from light | −20 °C, desiccated, from light |
| Short-Term Storage | 2–8 °C, up to 4 weeks | 2–8 °C, up to 4 weeks |
| Reconstituted Stability | Up to 28 days at 2–8 °C | Up to 28 days at 2–8 °C |
| Research Classification | Research Use Only (RUO) | Research Use Only (RUO) |
Lab Testing & Quality Assurance
Each compound in this blend — CJC-1295 No DAC and Ipamorelin — undergoes independent
analytical verification as a separate production batch. Baltic Peptides does not rely
solely on in-house testing; all quality data is confirmed by independent third-party
accredited laboratories prior to product release.
HPLC Purity Analysis
Reverse-phase HPLC confirms ≥99% purity for each compound individually, with quantified impurity profiling per batch.
Mass Spectrometry
ESI-MS or MALDI-TOF confirms the correct molecular mass for both CJC-1295 No DAC and Ipamorelin, verifying sequence integrity and ruling out adducts.
Certificate of Analysis
A separate, compound-specific COA is issued per production batch for both CJC-1295 No DAC and Ipamorelin. Both are available on request.
Third-Party Verification
Independent laboratory testing provides unbiased analytical validation, free from any conflict of interest in quality reporting.
Certificates of Analysis for both CJC-1295 No DAC and Ipamorelin are available upon request
via the Baltic Peptides support portal. Batch-specific documentation is archived and
fully traceable from synthesis through to final release testing.
Storage & Handling Guidelines
Both CJC-1295 No DAC and Ipamorelin are supplied as individual lyophilised vials.
The following conditions apply to each compound and should be maintained independently
throughout the storage lifecycle:
Lyophilised (Unopened)
Store at −20 °C, desiccated. Stable for 24 months from manufacture date under recommended conditions.
Short-Term (Unopened)
2–8 °C acceptable for up to 4 weeks. Retain vials in sealed state; protect from ambient moisture.
Reconstituted Solution
Store at 2–8 °C post-reconstitution. Both peptides are stable for up to 28 days. Avoid freeze-thaw cycling.
Handling Notes
Reconstitute each vial separately. Do not pre-mix lyophilised powders. Add solvent slowly to the vial wall; swirl gently — do not vortex.
⚠ Research Use Only — Important Notice
All products supplied by Baltic Peptides are designated exclusively for
in vitro research, preclinical investigation, and laboratory study
by qualified professionals operating within appropriately licensed or regulated
research environments.
CJC-1295 No DAC and Ipamorelin are not approved for human or veterinary
therapeutic use by any national medicines regulatory authority, including the
EMA, FDA, or MHRA. Neither compound is intended for self-administration, clinical
application, or use outside of legitimate controlled scientific research.
By completing a purchase, the buyer confirms their status as a qualified researcher
and explicitly acknowledges the research-use-only classification of these compounds.
Baltic Peptides assumes no liability for any use of these products beyond their
stated research designation.
Frequently Asked Questions
What is the CJC-1295 No DAC and Ipamorelin combination used for in research?
In preclinical and cell-based research settings, CJC-1295 No DAC and Ipamorelin are
used together to investigate dual-pathway stimulation of the somatotropic (GH) axis.
Primary research applications include:
- Pulsatile growth hormone secretion dynamics in hypothalamic-pituitary axis models
- Mechanistic comparison of GHRH-R and GHS-R1a signalling pathways and their interaction
- IGF-1 regulation in response to co-administration of complementary GH secretagogues
- Somatotroph cell biology and receptor-level pharmacology studies
- Preclinical models examining the additive effects of dual GH axis engagement
Neither compound is approved for any therapeutic indication. Both are supplied strictly
for laboratory-based scientific research.
What is the difference between CJC-1295 No DAC and CJC-1295 with DAC?
The critical structural difference lies in the Drug Affinity Complex (DAC) modification.
CJC-1295 with DAC incorporates a lysine-linked reactive group that enables covalent
binding to serum albumin, extending plasma half-life to approximately 8 days in animal
models and producing sustained, non-pulsatile GH elevation. CJC-1295 No DAC (Mod GRF 1-29)
lacks this modification, resulting in a half-life of approximately 30 minutes and a
kinetically distinct, pulsatile GH release profile. Researchers selecting between the
two variants typically do so based on whether their protocol requires physiologically
pulsatile or sustained tonic GH secretion patterns.
Why is Ipamorelin preferred over other GHRP compounds in research models?
Ipamorelin is distinguished from earlier growth hormone releasing peptides (GHRPs) such
as GHRP-2 and GHRP-6 primarily by its receptor selectivity profile. At equivalent GH-stimulating
concentrations in animal models, Ipamorelin demonstrates substantially lower stimulation of ACTH,
cortisol, and prolactin release compared to other GHRP-class compounds. This selectivity allows
researchers to examine GH axis modulation in greater isolation without the confounding
variable of concurrent HPA axis activation — making it a more controlled and interpretable
tool compound in somatotropic research.
How should CJC-1295 No DAC and Ipamorelin be stored after reconstitution?
Each compound should be reconstituted and stored separately. Once dissolved in sterile or
bacteriostatic water, both CJC-1295 No DAC and Ipamorelin solutions should be maintained
at 2–8 °C and used within 28 days. Repeated freeze-thaw cycling of reconstituted
solutions should be avoided, as this may promote peptide aggregation or degradation.
Lyophilised vials that have not yet been reconstituted should remain at −20 °C until
the point of use. Do not pre-mix the lyophilised powders in the same vial prior to
reconstitution; reconstitute each compound separately.
Is a Certificate of Analysis available for each compound?
Yes. Baltic Peptides issues a compound-specific Certificate of Analysis for every
production batch of both CJC-1295 No DAC and Ipamorelin. Each COA documents HPLC
purity results, mass spectrometry identity confirmation, lot number, testing dates,
and the analytical parameters applied. Researchers may request batch-specific
documentation for either or both compounds via the Baltic Peptides support portal.
All historical lot documentation is archived and available upon inquiry.
What solvent is recommended for reconstituting these peptides?
Both CJC-1295 No DAC and Ipamorelin are typically reconstituted using sterile water for
injection (WFI) or bacteriostatic water, achieving working concentrations of ≥1 mg/mL.
For Ipamorelin specifically, if solubility challenges are encountered at higher concentrations,
a dilute aqueous acetic acid solution (0.1–1%) can be used as an alternative vehicle, subject
to compatibility assessment with the downstream assay format. In all cases, solvent should
be introduced slowly along the vial wall and the solution swirled gently — not vortexed —
to avoid peptide degradation through mechanical shear.
What are the shipping conditions for CJC-1295 No DAC and Ipamorelin orders?
Both compounds are dispatched in lyophilised form, providing significant stability
advantages during transit compared to liquid peptide preparations. Orders are packaged
with appropriate temperature-protective materials to preserve product integrity throughout
shipping. Baltic Peptides dispatches from within the EU, reducing transit times and
customs exposure for European research institutions. Expedited shipping and cold-chain
packaging upgrades are available upon request for time-sensitive orders. Each shipment
includes product labelling stating lot number, storage conditions, and research-use classification.
Reviews
There are no reviews yet.